ecrin-mdr-crcClinical2014IPD Sharing (as of November 2018): NoOvarian CancerHepatoCellular CarcinomaLung CancerHead and Neck CancerGastric CancerEsophageal CancerPancreatic CancerColoRectal CancerPancreatic NeoplasmsBreast NeoplasmsBreast CancerLung NeoplasmsOvarian CancerLung CancerGastric CancerColorectal CancerEsophageal CancerHead And Neck CancerPancreatic CancerBreast NeoplasmsPancreatic NeoplasmsBreast CancerLung NeoplasmsHepatocellular CarcinomaInterventionalhttps://newmdr.ecrin.org/Study/2229591United States12No Evidence of DiseasePost Definitive SurgeryHigh Risk of RelapseImmunotherapyHuman Telomerase Reverse Transcriptase (hTERT)Post Adjuvant TherapyECRIN MDRCompletedfalsehTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of RelapseThis is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 or INO-1401 alone or in combination with INO-9012, delivered by electroporation in subjects with high-risk solid tumor cancer with no evidence of disease after surgery and standard therapy. Subjects will be enrolled into one of ten treatment arms. Subjects will be assessed according to standard of care. Restaging and imaging studies will be performed to assess disease relapse per NCCN guidelines. RECIST will be used to validate the findings in cases of relapse.2014-12-152229591NCT02960594